Stay updated with breaking news from Nat Rev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant...
163 are also involved in resistance to cisplatin, temozolomide and 5-fluorouracil via altering glycolysis in gastric cancer, glioblastoma and CRC, respectively. Interestingly, Fu et al reported that lncRNA plasmacytoma variant translocation 1 (PVT1) maintains Myc expression in Sjögren’s syndrome. This expression regulates proliferation and immune effects of CD4 + T cells by controlling glycolytic metabolism. 164 Investigating the role of the PVT1-T cell glycolysis axis in tumor models may provide a novel insight for improving T cell-based immunotherapy. The important role of lncRNAs-mediat...